MedTrace Logo

Baroreflex Activation Therapy in Left Ventricular Assist Device Patients Study

NCT06195046 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2025-07-23

No results posted yet for this study

Summary

This study will involve LVAD patients who have already received a clinically-indicated BAT (BAROSTIM) device. After recovery from LVAD implant, we will investigate the effects of BAT in a double-blind cross-over study design.

Conditions

  • Congestive Heart Failure

Interventions

DEVICE

Baroreflex Activation Therapy (BAT)

activation of BAROSTIM NEO system that affects autonomic modulation with BAT therapy.

Sponsors & Collaborators

  • CVRx, Inc.

    collaborator INDUSTRY

  • Medical University of South Carolina

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2025-07-01
Completion
2025-07-01
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06195046 on ClinicalTrials.gov